

Implementation of trastuzumab in adjuvant
treatment of breast cancer and guideline
adherence in the Netherlands
&
Spatial variation in stage distribution in
colorectal cancer in the Netherlands

Sabine Siesling, PhD
Head of dept. Research
Comprehensive Cancer Centre North East



Implementation of trastuzumab in adjuvant
treatment of breast cancer and guideline
adherence in the Netherlands
&
Spatial variation in stage distribution in
colorectal cancer in the Netherlands

Sabine Siesling, PhD
Head of dept. Research
Comprehensive Cancer Centre North East



Trastuzumab / Herceptin

Immunotherapy

Targets on HER2 receptor




Timeline introduction adjuvant trastuzumab

16 May 2005: presentation 2 USA studies + HERA-study at ASCO

15 Sept 2005: publication new guideline

12 June 2005: NVMO advice is published



Guideline

Adjuvant trastuzumab should be used in:

- Stage I-III
- HER2 + (FISH/IHC test) women
- In combination with adjuvant chemotherapy



NRC 

03-12-2005

Kankerpatiënt loopt duur medicijn mis

Minister weigert extra geld

donderdag 22 februari 2007



Niet altijd beste medicijn voor kankerpatiënt

UTRECHT - Kankerpatiënten krijgen in Nederland niet altijd de medicijnen waar ze het beste mee geholpen zijn. Door krapte in hun budgetten kiezen ziekenhuizen voor goedkopere medicijnen die minder effectief zijn.

de Volkskrant

Patiënt krijgt duur medicijn niet meer

14 november 2007

Medisch Contact

Richtlijnen borstkanker wél gevolgd
Publicatie: Nr. 39 - 26 september 2008



Aim of this study

- To identify the percentage of women with HER2-positive breast cancer
- To evaluate the implementation of trastuzumab in clinical practice
- To evaluate differences between regions in the Netherlands



Patients and methods

- Selection from the Netherlands Cancer Registry
- Inclusion:
 - women
 - invasive breast cancer (stage I-III)
- Exclusion:
 - Distant metastases
 - Neo-adjuvant chemotherapy
- Period: 1 Sept 05 – 1 Jan 07 (16 months)
- Number of patients: 14.934
- Her2 status and treatment was regularly registered



Regions of the Comprehensive Cancer Centres in the Netherlands



Aim of this study


- To identify the percentage of women with HER2-positive breast cancer
- To evaluate the implementation of trastuzumab in clinical practice
- To evaluate differences between regions in the Netherlands

HER2-positivity and age

	Patients N	Her2-positive %
<40	785	22,3
40-49	2.802	15,5
50-59	4.006	14,4
60-69	3.599	11,1
70+	3.738	9,2
Total	14.937	12,6




% of patients with a HER2-positive tumour, by age



Vertical lines: range between different CCC regions

% of patients with HER2 status unknown / not tested, by age




Vertical lines: range between different CCC regions

Aim of this study


- To identify the percentage of women with HER2-positive breast cancer
- To evaluate the implementation of trastuzumab in clinical practice
- To evaluate differences between regions in the Netherlands

% of HER2+ patients receiving trastuzumab, by age



Vertical lines: range between different CCC regions

% of HER2+ patients receiving trastuzumab, over time



Vertical lines: range between different CCC regions

Reasons to withhold trastuzumab

	N	%
Cardio toxicity	19	28,8
Patient refusal	14	21,2
Age	7	10,6
Other	2	3,0
No information about trastuzumab found	24	36,4
Total	66	100,0


iKNO

Aim of this study

- To identify the percentage of women with HER2-positive breast cancer
- To evaluate the implementation of trastuzumab in clinical practice
- To evaluate differences between regions in the Netherlands

iKNO

% of HER2+ patients receiving trastuzumab, by region



KNO

Conclusion (1)

- NCR: great value to evaluate the implementation of adjuvant trastuzumab since introduction
- 13% of patients has HER2-positive tumour
- % HER2-positive tumours is markedly related to age

KNO

Conclusion (2)

16 May 2005: presentation 2 USA studies + HERA-study at ASCO

15 Sept 2005: publication new guideline



12 June 2005: NVMO advice is published

Sept - Dec 2005:

>90% of patients received trastuzumab

Conclusion (3)

- Implementation trastuzumab fast, but with some regional variation
- Legitimate reasons to withhold trastuzumab were found for most patients (64%)

donderdag 22 februari 2007

AD Niet altijd beste medicijn voor kankerpatiënt

www.ad.nl

UTRECHT - Kankerpatiënten krijgen in Nederland niet altijd de medicijnen waar ze het beste mee geholpen zijn. Door krapte in hun budgetten kiezen ziekenhuizen voor goedkopere medicijnen die minder effectief zijn.



de Volkskrant



Patiënt krijgt duur medicijn niet meer

14 november 2007



Medisch Contact

Richtlijnen borstkanker wél gevolgd

Publicatie: Nr. 39 - 26 september 2008

Yes, we did



KNO